What Is Acute Kidney Injury?
The condition known as acute kidney injury (AKI) occurs when the kidneys are abruptly unable to filter waste products out of the blood. This may occur in a matter of hours or days. AKI typically appears within 48 hours for most people, although occasionally, it takes up to seven
days.
What Are the Signs of Acute Kidney Injury?
Symptoms of acute kidney injury include -
-
Generating either no urine or less urine than normal.
-
Swelling in the foot, ankles, or legs.
-
Tiredness or exhaustion.
-
Breathlessness or difficulty breathing.
-
Disorientation or mood swings.
-
Diminished appetite or a lack of desire to eat.
-
Nausea.
-
Pressure or pain in the chest.
-
Seizures or unconsciousness.
What Is the Prevalence of AKI in Cirrhosis?
Patients with cirrhosis have been shown to have a prevalence of renal impairment ranging from 14 to 50 percent. According to estimates, the prevalence is 20 percent in hospitalized patients with severe cirrhosis and almost 50 percent in individuals with cirrhosis and ascites.
What Are the Causes of AKI in Liver Disease?
The causes of AKI include the following:
-
AKI can be caused by a variety of factors, including hepatorenal syndrome type 1 (HRS-1). A potentially fatal side effect of severe liver disease that impairs renal function and results in prerenal acute kidney failure.
-
Prerenal azotemia (an unusually high quantity of nitrogen compounds in the blood) may result from inadequate cardiac output due to hepatorenal syndrome 1, urine losses from diuretics prescribed for ascites, or gastrointestinal fluid losses brought on by laxatives prescribed as a prophylactic measure for hepatic encephalopathy (an altered state of consciousness brought on by liver failure).
-
Prolonged prerenal azotemia, hemorrhagic shock (related to gastrointestinal bleeding), or septic shock (due to spontaneous bacterial peritonitis (SBP) are the possible causes of ischemic acute tubular injury (ATI).
-
AKI can result from renal vein congestion, as observed in cases of right ventricular failure from portopulmonary hypertension (PoPHTN), congestive heart failure from cirrhotic cardiomyopathy (a particular cardiac malfunction that is thought to be common in 50 percent of patients with liver cirrhosis), or abdominal compartment syndrome (a potentially fatal illness brought on by elevated abdominal pressure) brought on by tight ascites (a fluid accumulation in the abdomen, frequently brought on by serious liver disease).
-
Acute glomerulonephritis can be caused by hepatitis C (HCV) or hepatitis B (HBV)- associated membranoproliferative GN (MPGN) or IgA nephropathy (IgAN). Proton pump inhibitors (PPIs) and antibiotics administered for infections can also cause acute interstitial nephritis.
-
Although obstructive uropathy is uncommon in cirrhosis, it can happen to patients receiving Midodrine treatment for HRS-1.
-
In the hospital setting, patients with cirrhosis are often offered antibiotics. Hence, antibiotics may induce acute kidney damage (AKI) through an allergic reaction that results in acute interstitial nephritis (AIN) or toxic acute tubular injury through direct tubular cell toxicity.
How to Determine the Cause of AKI?
Changes in blood creatinine and urine output are used clinically to evaluate acute impairment of renal function. The pretest probability of a particular etiology of AKI is determined by the history and physical examination, which continue to be the cornerstones of the diagnostic strategy. The distinction will frequently be informed by the clinical situation (that is, inpatient versus outpatient), taking into account the possibility of hepatorenal syndrome type 1 (HRS-1), a form of AKI specific to cirrhosis. Important components of laboratory testing include microscopic analysis of the urine sediment, full urinalysis, and urine chemistries. To rule out obstructive uropathy as the etiology of AKI, kidney ultrasonography is frequently utilized. Tests have been conducted on urine biomarkers to evaluate AKI in cirrhosis.
Recent data has surfaced about the efficacy of urine and serum biomarkers, such as liver-type fatty acid binding protein (L-FABP), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), and neutrophil gelatinase-associated lipocalin (NGAL), in differentiating ATN (acute tubular necrosis) from HRS. Since these biomarkers are higher in AKI owing to ATN than HRS or prerenal causes of AKI, they are promising and may help identify ATN from HRS type I.
According to one study, patients undergoing liver transplantation may accurately be diagnosed with HRS as the cause of their renal failure based on the levels of the chemical endothelin-1 (ET-1) released by vascular endothelial cells. In patients with cirrhosis, ascites, and normal renal function, cyclostatin C was also discovered to be an independent predictor of HRS, which may be helpful in identifying individuals who are at risk for HRS.
How to Manage AKI in Liver Diseases?
A comprehensive evaluation of the drug list, the removal of offending medications, volume expansion in patients with suspected hypovolemia, and the timely diagnosis and treatment of bacterial infection are all important components of the general therapy of AKI in cirrhosis patients.
Volume expansion and stopping problematic medications, specifically diuretics and lactulose, are the main ways to address prerenal AKI (in the setting of severe diarrhea). Albumin is used to expand volume in individuals with hypoalbuminemia at a dose of 1 gram per kilogram body weight daily, up to a daily maximum of 100 grams. Large-volume paracentesis (a process that drains fluid accumulation in the abdomen) with albumin supplementation may be used to treat symptomatic ascites while diuretics are withheld. Serious hypovolemia, undiagnosed AKI, and sepsis can all lead to ATN-induced intrarenal damage.
Hemodialysis may be necessary for patients with intrarenal damage to treat metabolic acidosis, hyperkalemia, volume overload, and symptomatic uremia. Treatment with antivirals may improve renal function in patients with intrinsic kidney impairment caused by glomeruli nephropathies associated with hepatitis C.
How Does Kidney Replacement Therapy (KRT) Affect AKI Management?
The underlying etiology determines how individuals with AKI and liver disease should be managed. When medicinal management fails, KRT is evaluated on an individual basis. KRT may be administered to patients who are determined to be candidates for liver transplantation until their renal function returns. While determining the transplantation status, it is acceptable to offer KRT to patients who are being assessed for a liver transplant and whose prognosis is unclear. However, a multidisciplinary approach involving patients and their families must be taken into consideration when evaluating the possible hazards and advantages for patients who are not eligible for transplantation of the liver. Offering KRT might be considered ineffective in an intensive care situation if there are no indications of AKI reversibility and multiorgan failure. For hemodynamically unstable patients, continuous KRT is the preferred treatment option, whereas more stable patients may try intermittent hemodialysis.
Conclusion:
In conclusion, individuals with severe cirrhosis frequently get acute kidney injury, which is linked to a significant risk of morbidity and death. Improving outcomes requires early diagnosis and treatment of cirrhosis as well as recognition of the common causes of AKI. One specific treatment for those with HRS-1 is vasoconstrictor therapy. When medical therapy fails, and a patient is either eligible for liver transplantation, has a significant possibility of recovering their kidneys, or would benefit from the operation, KRT should be made available to them.
